Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Multitude Therapeutics Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05498597CT.gov AMT-151 in Patients With Selected Advanced Solid Tumours | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Mucinous Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Amt-151 (this asset) | Multitude Therapeutics Inc. | P1 | CC · 43 |
| Carboplatin | Ohio State University Comprehensive Cancer Center | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | B |
| Adriamycin | National Cancer Institute (NCI) | P2 | B |
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | Mayo Clinic | P2 | B |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | B |
| Elesclomol | GOG Foundation | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
+9 more in the Ovarian Mucinous Adenocarcinoma cohort
Other indications for Amt-151
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Carcinoma | — | P1 | CC · 43 |
| Endometrium Adenocarcinoma | — | P1 | CC · 43 |
| Endometrial Serous Adenocarcinoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinOhio State University Comprehensive Cancer CenterBBB
- Cis-Diamminedichloroplatinum IiOhio State University Comprehensive Cancer CenterBB
- CyclophosphamideRoswell Park Cancer InstituteB
- AdriamycinNational Cancer Institute (NCI)B
- Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide SymporterMayo ClinicB
Citation
Floatz Terminal. Amt-151 in Ovarian Mucinous Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/amt-151-ovarian-mucinous-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →